HGEN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Jan 2024 @ 13:45):

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'...

Stats
Today's Volume	2.06M
Average Volume	341 846
Market Cap	23 816.00
EPS	$0 ( 2024-03-28 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.000392
ATR14	$0.00100 (1 000.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-18	Chappell Dale	Sell	276 210	Common Stock, $0.001 par value
2023-10-18	Chappell Dale	Sell	75 887	Common Stock, $0.001 par value
2023-10-18	Chappell Dale	Sell	34 253	Common Stock, $0.001 par value
2022-07-27	Buxton Cheryl	Buy	78 362	Stock Option (Right to Buy)
2022-07-27	Hohneker John	Buy	63 195	Stock Option (Right to Buy)

INSIDER POWER
40.26
Last 98 transactions
Buy: 5 830 886 \| Sell: 2 957 610

Volume Correlation

Long: 0.10 (neutral)

Short: 0.00 (neutral)

Signal:(38.548) Neutral

Humanigen, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Humanigen, Inc. Correlation - Currency/Commodity

-0.77
( moderate negative )

-0.84
( strong negative )

0.00
( neutral )

-0.58
( weak negative )

0.70
( moderate )

Humanigen, Inc. Financials

Annual	2022
Revenue:	$2.51M
Gross Profit:	$2.51M (100.00 %)
EPS:	$-1.180

Q1	2023
Revenue:	$221 000
Gross Profit:	$221 000 (100.00 %)
EPS:	$-0.0348

Q4	2022
Revenue:	$221 000
Gross Profit:	$221 000 (100.00 %)
EPS:	$-0.790

Q3	2022
Revenue:	$221 000
Gross Profit:	$221 000 (100.00 %)
EPS:	$-0.230

Financial Reports:

No articles found.

Humanigen, Inc.

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.